Valneva (NASDAQ:VALN) Shares Gap Down – Time to Sell?

Valneva SE (NASDAQ:VALN) gapped down prior to trading on Tuesday . The stock had previously closed at $6.41, but opened at $6.22. Valneva shares last traded at $6.23, with a volume of 2,395 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently commented on VALN shares. Guggenheim dropped their target price on shares of Valneva from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Valneva in a research report on Tuesday, April 15th.

Valneva Trading Down 3.6%

The stock has a 50-day moving average of $6.55 and a two-hundred day moving average of $5.84. The company has a market cap of $516.87 million, a P/E ratio of -47.54 and a beta of 1.85. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Valneva (NASDAQ:VALN) last issued its earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.27. The business had revenue of $51.79 million during the quarter, compared to analysts’ expectations of $41.80 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. On average, equities research analysts predict that Valneva SE will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

A number of hedge funds have recently modified their holdings of the business. ABC Arbitrage SA bought a new stake in Valneva during the fourth quarter valued at about $84,000. GAMMA Investing LLC purchased a new position in shares of Valneva during the 1st quarter valued at about $94,000. Finally, Wells Fargo & Company MN grew its stake in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after acquiring an additional 30,859 shares during the period. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.